On August 27, 2013, global education company Pearson plc announced it had acquired BioBehavioral Diagnostics (BioBDx) and its flagship Quotient System, a computerized attention deficit hyperactivity disorder (ADHD) assessment and management system approved by the U.S. Food and Drug Administration (FDA) in 2002 to aid in diagnosing ADHD. Financial terms of the transaction were not disclosed.
For Pearson, the acquisition provides an entry into health care markets, and a way of meeting its goal of providing for educational needs across a spectrum of individuals. Pearson plans to focus on increasing awareness and use of the Quotient . . .
Restricted Content
You must be an Elite member to view this resource.
